eFront, provider of financial solutions for managing alternative investments, has announced that Forbion Capital Partners has gone live with FrontInvest to support its front-office investment operations. The firm will be using FrontInvest’s deal flow management and CRM modules to enhance automation in its front-office and improve reporting quality. Meanwhile eFront anticipates finalizing the complete implementation of the fund and investor management, portfolio, and general ledger modules during the remaining part of this quarter. The move brings significant efficiency savings as well as enhancements to internal controls and risk management.
With offices in the Netherlands (Naarden) and Germany (Munich), Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies committed to product development. Current assets under management exceed EUR 400M split across four active funds that are invested in 29 active portfolio companies. Forbion also co-manages Biogeneration Ventures, an early-stage fund investing in Dutch academic start ups.
After an extensive evaluation of the market, Forbion Capital Partners selected eFront FrontInvest for its superior support across the whole deal flow management lifecycle. The solution’s flexible technology will strengthen the due diligence process providing real-time analysis of the investment pipeline by industrial sector, pipeline stage, owner, or other relevant criteria while operational metrics highlight pain points in the pipeline management process.
Post-investment benchmarking enhances transparency in performance measurement and comprehensive information tracking, including company and co-investment data, and ensures a complete and long-term view of the portfolio is provided. This centralized data hub also contains all past, present and outstanding client communications as well as information on meetings and other relevant tasks relating to an organization. The intelligence this provides streamlines workflows and ensures investor relations, portfolio management and other related business processes are run as effectively and efficiently as possible.
“We are in the business of investing in the highest quality projects in the Life Sciences and Biomedical Technology sectors and eFront’s powerful opportunity identification and deal flow management will support us in this strategy,” said Holger Reithinger, Partner at Forbion Capital Partners. “From a quality and efficiency perspective, we are committed to operational excellence in all that we do. The enhancements to business processes that FrontInvest will provide will ensure we continue to achieve this.”
Philippe Verboogen, COO at eFront for Continental Europe, added: “Forbion Capital Partners’ long-term success is due to the exceptional competencies and expertise of its people. They wanted a software provider with the same values, and this, along with our proven track record implementing front-office solutions for fund managers, clearly positioned us as the preferred provider.”